Product News
Filter News
Found 273,334 articles
-
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
3/19/2024
Vicore Pharma Holding AB announced FDA Breakthrough Device Designation status for AlmeeTM, a 9-week digital cognitive behavioral therapy, to be used as an adjunct treatment of anxiety symptoms related to PF.
-
CGI selected by Centers for Medicare & Medicaid Services to improve Medicare access for more than 65 million beneficiaries nationwide
3/19/2024
CGI Federal Inc., a wholly-owned U.S. operating subsidiary of CGI Inc., has been awarded a single award, firm-fixed price contract by the Centers for Medicare & Medicaid Services to help improve access to Medicare for millions of beneficiaries by modernizing the agency's Health Plan Management System.
-
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC
3/19/2024
Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement.
-
Biovica rReceives Positive Patent Notification for Immunotherapies
3/19/2024
Biovica International Biovica has received a positive International Preliminary Report on Patentability covering the use of TKa as a prognostic and monitoring marker in cancer treatment outside the CDK 4/6 inhibitor space, expanding the market potential for the DiviTum TKa technology by four to six times.
-
PureTech Proposes $100 Million Capital Return
3/19/2024
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces a proposed capital return of $100 million to its shareholders by way of a tender offer.
-
Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC
3/19/2024
Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
-
IRLAB’s Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson’s Disease Psychosis
3/19/2024
IRLAB Therapeutics AB announced that a scientific paper reporting the effects of IRLAB's candidate drug mesdopetam in a preclinical model of Parkinson's disease psychosis has been published in the journal Neurotherapeutics.
-
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
3/19/2024
Innovent Biologics, Inc. announced that the primary endpoint has been met in the second Phase 2 clinical study of efdamrofusp alfa high-dose, a recombinant human VEGFR-Fc-Human CR1 fusion protein injection, in Chinese subjects with neovascular age-related macular degeneration.
-
Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo
3/19/2024
Cognizant is advancing the application of generative AI technology with the NVIDIA BioNeMo platform to solve complex challenges of drug discovery in the life sciences industry, such as improving productivity in the development process and increasing the speed at which new, life-saving treatments can be brought to market.
-
BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease
3/19/2024
BioArctic AB announced that BioArctic's founder, Professor Lars Lannfelt, was awarded the European Grand Prix for his research on Alzheimer's disease at the anniversary gala for La Fondation Recherche Alzheimer in Paris on March 18.
-
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
3/19/2024
XORTX Therapeutics Inc. is pleased to provide a summary of Company’s achievements in 2023 and objectives planned for 2024.
-
Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office
3/19/2024
Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, announced that it is one of the leading patent applicants at the European Patent Office.
-
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
3/19/2024
AstriVax is pleased to welcome Dr. Gregory Fanning as its Chief Business Officer.
-
Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.
-
Virtual Incision’s MIRA Surgical System to be Featured Among Elite AI-Enabled Innovations at NVIDIA GTC
3/18/2024
Virtual Incision Corporation, the developer of the MIRA Surgical System, announced the company will showcase MIRA at NVIDIA GTC.
-
American Association for Anatomy Publishes New Guidelines for The Ethical Management of Human Remains
3/18/2024
The American Association for Anatomy released the whitepaper "Recommendations for the Management of Legacy Anatomical Collections" to provide ethical guidance on the treatment of human remains in public and private institutions, many of which were collected before today's standard of informed consent.
-
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal
3/18/2024
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announces two commercial deals that signal its expansion in Europe.
-
Nexus Pharmaceuticals Launches Baclofen Injection, USP
3/18/2024
Today, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP.
-
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
3/18/2024
Anavex Life Sciences Corp today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.
-
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
3/18/2024
Arch Biopartners Inc. announced today that it has published a peer reviewed paper in the British Medical Journal Open (BMJ Open) detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus.